Literature DB >> 23692186

Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.

Anna V Kutina1, Anna S Marina, Elena I Shakhmatova, Yury V Natochin.   

Abstract

The aim of the present study was to clarify the mechanisms mediating the effect of a glucagon-like peptide-1 (GLP-1) mimetic on solute-free water excretion in rats. The GLP-1 mimetic exenatide (0.05-5.0 nmol/kg, i.m.), alone and in combination with either a vasopressin V2 receptor antagonist (15 nmol/kg, i.p.) or vasopressin (0.01 nmol/kg, i.m.), was injected into control and water-loaded (water 10-50 mL/kg, p.o., or 50 mL/kg of 0.6% NaCl, i.p.) rats to evaluate the role of collecting duct water permeability in the hydrouretic effect. Urinary prostaglandin (PG) E2 excretion and the effects of diclofenac (5 mg/kg, i.m.) and GLP-1 receptor antagonist (0.15 μmol/kg, i.p.) on exenatide action were assessed. The hydrouretic effect of exenatide was equivalent following oral or intraperitoneal water loading, and was proportional to the volume of water administered. Injection of exenatide, under conditions of a maximal decrease in collecting duct water permeability (V2 receptor antagonist administration in water-loaded rats), additionally stimulated solute-free water formation. The GLP-1 receptor antagonist weakened the hydrouretic action of exenatide. Urinary PGE2 excretion increased following water loading (47 ± 6 vs 24 ± 4 ng/kg over a 30 min period) and was enhanced as a result of additional exenatide injection (69 ± 10 ng/kg). Diclofenac and vasopressin delayed the hydrouretic effect of exenatide. The effect of exenatide on solute-free water clearance in water-loaded rats is presumably mediated by stimulation of PGE2 secretion and reinforcement of tubular fluid influx from the proximal tubule to the distal segment of the nephron and collecting duct.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  exenatide; glucagon-like peptide-1; kidney; prostaglandin E2; solute-free water clearance; vasopressin; water permeability

Mesh:

Substances:

Year:  2013        PMID: 23692186     DOI: 10.1111/1440-1681.12119

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  Stimulus for Glucagon-Like Peptide 1 Secretion in Rats.

Authors:  Yu V Natochin; A V Kutina; A S Marina; E I Shakhmatova
Journal:  Dokl Biol Sci       Date:  2018-05-22

2.  The role of incretin as an integrator of sodium and water balance regulation.

Authors:  Yu V Natochin; A S Marina; A V Kutina
Journal:  Dokl Biol Sci       Date:  2014-11-05

3.  Stimulation of glucagon-like peptide-1 secretion by water loading in human.

Authors:  A S Marina; A V Kutina; E I Shakhmatova; E V Balbotkina; Yu V Natochin
Journal:  Dokl Biol Sci       Date:  2015-01-06

4.  The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis.

Authors:  Yu V Natochin; A S Marina; A V Kutina; E V Balbotkina; T A Karavashkina
Journal:  Dokl Biol Sci       Date:  2016-09-07

5.  The Cascade System of Osmotic Homeostasis Regulation.

Authors:  Yu V Natochin; A S Marina; E I Shakhmatova
Journal:  Dokl Biol Sci       Date:  2020-04-27

Review 6.  The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

Authors:  Marcel H A Muskiet; Mark M Smits; Linde M Morsink; Michaela Diamant
Journal:  Nat Rev Nephrol       Date:  2013-12-24       Impact factor: 28.314

7.  Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors.

Authors:  Jonas Ronn; Elisa P Jensen; Nicolai J Wewer Albrechtsen; Jens Juul Holst; Charlotte M Sorensen
Journal:  Physiol Rep       Date:  2017-12

8.  Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.

Authors:  Lennart Tonneijck; Mark M Smits; Marcel H A Muskiet; Trynke Hoekstra; Mark H H Kramer; A H Jan Danser; Michaela Diamant; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetologia       Date:  2016-04-01       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.